Ensuring incentives for innovation and access to medicines: The balance struck in the Trans-Pacific Partnership Agreement on intellectual property (patent and regulatory data) protection for pharmaceutical products

cepal.bibLevelDocumento Completo
cepal.callNumberLC/W.720
cepal.docTypeDocumentos de proyectos e investigación
cepal.jobNumberS1600773_en
cepal.regionalOfficeWashington
cepal.sdg9
cepal.sdg17
cepal.topicEngMONITORING OF INTERNATIONAL/REGIONAL AGREEMENTS
cepal.topicEngTRADE IN GOODS AND SERVICES
cepal.topicEngTRADE POLICY AND TRADE AGREEMENTS
cepal.topicSpaCOMERCIO DE BIENES Y SERVICIOS
cepal.topicSpaMONITOREO DE ACUERDOS INTERNACIONALES/REGIONALES
cepal.topicSpaPOLÍTICA COMERCIAL Y ACUERDOS COMERCIALES
cepal.workareaEngINTERNATIONAL TRADE AND INTEGRATION
cepal.workareaSpaCOMERCIO INTERNACIONAL E INTEGRACIÓN
dc.contributor.authorPlank-Brumback, Rosine M.
dc.coverage.spatialEngLATIN AMERICA AND THE CARIBBEAN
dc.coverage.spatialSpaAMERICA LATINA Y EL CARIBE
dc.date.accessioned2016-11-08T14:15:40Z
dc.date.available2016-11-08T14:15:40Z
dc.date.issued2016-10-31
dc.description.abstractThe United Nations Economic Commission for Latin America and the Caribbean (ECLAC) commissioned this study to analyze the implications of the balance struck under the Trans-Pacific Partnership Agreement (TPPA) between the right to health and access to next-generation medicines on the one hand, and on the other, the private right to intellectual property protection and the need to maintain profit-earning incentives to spur innovation and research and development. The study focuses on the patent and data-related intellectual property protection provisions of the TPPA, specifically regarding pharmaceutical (small-molecule and biologic ) products, including on patent duration, linkage and term extensions as well as clinical test data protection and market exclusivity. The study considers the position of the United States in this respect, as it has been and remains the world’s principal demandeur for high intellectual property rights (IPR) standards in trade agreements, including the TPPA.
dc.description.tableOfContentsIntroduction .-- I. Multilateral trade rules for IPRs on pharmaceutical products .-- II. The U.S. approach to intellectual property protection on pharmaceutical products and the factors driving it .-- III. Key trends in the global and regional pharmaceutical industry .-- IV. Key TPPA provisions affecting pharmaceutical products .-- V. Conclusions on striking the appropriate balance between ensuring incentives for innovation and access to medicine.
dc.formatTexto
dc.format.extent73 páginas.
dc.format.mimetypeapplication/pdf
dc.identifier.unSymbolLC/WAS/W.8
dc.identifier.unSymbolLC/W.720
dc.identifier.urihttps://hdl.handle.net/11362/40723
dc.language.isoeng
dc.physicalDescription73 p.
dc.publisherECLAC
dc.publisher.placeSantiago
dc.rights.coarDisponible
dc.subject.unbisEngECONOMIC AGREEMENTS
dc.subject.unbisEngTRADE NEGOTIATIONS
dc.subject.unbisEngINTERNATIONAL TRADE
dc.subject.unbisEngINTELLECTUAL PROPERTY
dc.subject.unbisEngPHARMACEUTICALS
dc.subject.unbisEngTRADE POLICY
dc.subject.unbisEngINNOVATIONS
dc.subject.unbisSpaACUERDOS ECONOMICOS
dc.subject.unbisSpaNEGOCIACIONES COMERCIALES
dc.subject.unbisSpaCOMERCIO INTERNACIONAL
dc.subject.unbisSpaPROPIEDAD INTELECTUAL
dc.subject.unbisSpaPRODUCTOS FARMACEUTICOS
dc.subject.unbisSpaPOLITICA COMERCIAL
dc.subject.unbisSpaINNOVACIONES
dc.titleEnsuring incentives for innovation and access to medicines: The balance struck in the Trans-Pacific Partnership Agreement on intellectual property (patent and regulatory data) protection for pharmaceutical products
dc.type.coarlibro
dspace.entity.typePublication
relation.isAuthorOfPublication732cda85-d6cd-4d75-840c-78408791d812
relation.isAuthorOfPublication.latestForDiscovery732cda85-d6cd-4d75-840c-78408791d812
Descargar
Bloque original
Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
S1600773_en.pdf
Tamaño:
497.78 KB
Formato:
Adobe Portable Document Format
Descripción:
Document in English